Biologics APIs

Managing mRNA Instability During Formulation, Manufacturing, and Shipment

December 03, 2022

Unique solutions are required to protect inherently unstable messenger RNA.

FDA Expands Oversight of Cell and Gene Therapies

October 12, 2022

CBER maps modernization plan to handle surge in research and applications.

Biologic Standards in the Pharmacopoeias: An Update

October 02, 2022

Awareness of recently implemented—or ongoing—advances by the pharmacopoeias can help biotherapeutic manufacturers remain compliant with current requirements.

Synthego Aims to Accelerate Drug Discovery with New Engineered Cell Libraries

August 04, 2022

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Progress in the Development of CAR NK-Cell Therapies

August 03, 2022

Further advances in construct design and manufacturing scalability are still needed.

Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

August 02, 2022

Novasep-PharmaZell will increase API production capacity at its Mourenx site with €7.3M investment.

VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies

July 08, 2022

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

LG Chem Renews License with Avacta for IND Studies

July 08, 2022

LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

June 27, 2022

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

Lonza, IBF Collaborate to Support Development and Manufacturing of Biologics and Small Molecules

May 26, 2022

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.